Image Credit: Love Employee / Shutterstock In a recent study published in the journal Nature Medicine , researchers compared major adverse cardiovascular events (MACE) between glucagon-like peptide-1 (GLP-1) receptor agonists and comparators, benchmarking real-world estimates against randomized trial data to guide clinical decision-making
Explore human clinical research and oral options If youd like to explore human clinical evidence and research-backed oral options, visit Tonums research page to learn more about trial results and product studies
Some patients should avoid semaglutide, while others need a deeper medical review before treatment begins
GLP-1 drugs stimulate the release of insulin when blood sugar is elevated, inhibit the release of glucagon (a hormone that raises glucose), and slow stomach emptying, helping people feel fuller for longer
Each semaglutide product has specific administration requirements
Instruct patients to inform healthcare providers prior to any planned surgeries or procedures if they are taking RYBELSUS Adverse Reactions Most common adverse reactions (incidence 5%) are nausea, abdominal pain, diarrhea, decreased appetite, vomiting and constipation Drug Interactions RYBELSUS stimulates insulin release in the presence of elevated blood glucose concentrations
